Elekta AB (publ) (EKTAF) Stock

About Elekta AB (publ)

Elekta AB (publ) is a global medical technology enterprise providing advanced clinical tools for the treatment of cancer and neurological conditions. Their extensive product portfolio includes leading solutions for radiotherapy, such as Versa HD for brain metastases, the innovative Elekta Unity MR-Linac, Elekta Harmony linear accelerator, and systems like Elekta Infinity and Elekta Synergy for diverse radiotherapy needs, including advanced image guidance. They also offer comprehensive treatment management, quality assurance, and motion management technologies. For multidisciplinary cancer care, Elekta provides MOSAIQ Plaza and the Elekta Axis Cloud managed hosting service. In brachytherapy, their offerings range from the image-guided Elekta Studio and mobile CT ImagingRing to specialized applicators like Venezia and Geneva for cervical cancer, supported by the Oncentra Brachy smart tool and Flexitron afterloader. Their renowned Leksell Gamma Knife series – Icon, Perfexion, and Lightning – delivers precise and accelerated radiosurgery for various indications. Additionally, Elekta supplies neurosurgery products, including the Leksell Vantage and Leksell Stereotactic Systems for both intracranial and minimally invasive procedures. Established in 1972, the company maintains its headquarters in Stockholm, Sweden.

Elekta AB (publ) (EKTAF) stock trades at $5.25 with a market capitalization of $1.93B. The stock is valued at a price-to-earnings (P/E) ratio of -3.80, price-to-book of 0.27, price-to-sales of 0.12. Over the past 52 weeks the stock has ranged between $4.48 and $6.83, and currently trades 23.1% below its 52-week high. It pays a dividend yielding 4.95%.

On profitability, Elekta AB (publ) generates a return on equity (ROE) of -7.33%, return on capital employed of 7.44%, an operating margin of 2.60%, a net profit margin of -3.11%.

Official website: www.elekta.com